<DOC>
	<DOCNO>NCT00392067</DOCNO>
	<brief_summary>To compare efficacy safety two different dose combination LEO19123 ( calcipotriol LEO80122 ) LEO19123 cream vehicle 3 week treatment patient atopic dermatitis</brief_summary>
	<brief_title>LEO19123 Cream Treatment Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>Clinical diagnosis atopic dermatitis accord Hanifin Rajka The score erythema , induration/papulation , excoriation lichenification , four five clinical sign Total Severity Score , least correspond moderate involvement , i.e . severity great equal 2 , Visit 1 Treatment area amenable topical treatment Attending hospital outpatient clinic private practice dermatologist Following verbal write information trial , patient must provide sign date informed consent study related activity carry , include activity relate washout period Males 1850 year Systemic treatment immunosuppressive drug ( e.g . methotrexate , cyclosporine , azathioprine ) corticosteroid within 4 week prior randomisation . ( Inhaled intranasal steroid asthma rhinitis may use ) PUVA UVB therapy within 4 week prior randomisation Topical treatment immunomodulators ( pimecrolimus , tacrolimus ) corticosteroid WHO group III IV within 2 week prior randomisation Other topical therapy treatment area ( except use emollient entire body use hydrocortisone cream 1 % AD lesion head neck ) within 1 week prior randomisation Use kind treatment ( drug , nondrug ) AD study except use : Investigational product trunk limbs lesion treatment phase Hydrocortisone cream 1 % head neck lesion Emollient entire body Use antihistamines study Current diagnosis exfoliative erythrodermia Clinical infection ( impetiginised atopic dermatitis ) treatment area Planned exposure amount sun ultraviolet light study may affect atopic dermatitis Known suspect hypersensitivity component ( ) investigational product Known suspect severe renal insufficiency severe hepatic disorder Patients history/signs/symptoms suggestive abnormality calcium homeostasis associate clinically significant hypercalcaemia Patients history cancer include skin cancer Patients history immunocompromised disease ( e.g . lymphoma , HIV , WiskottAldrich Syndrome ) Current participation interventional clinical trial Patients receive treatment nonmarketed drug substance ( i.e . agent yet make available clinical use follow registration ) within 4 week prior randomisation Previously randomise study Patients know suspected able comply trial protocol ( e.g . alcoholism , drug dependency , psychotic state )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>